CA-PACKETFABRIC
9.12.2020 15:17:13 CET | Business Wire | Press release
PacketFabric , an innovator of on-demand connectivity to the secure, private internet, today announced it launched flat rate pricing for hybrid cloud connectivity across the U.S. and Europe. With this innovative pricing strategy, PacketFabric continues to lead the market disruption of networking and cloud computing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201209005337/en/
PacketFabric’s new democratized pricing is $100 per month for hosted hybrid cloud connections up to 1Gbps, for both metro and long-haul capacity in the United States and Europe. With this new pricing strategy, PacketFabric is making cloud connectivity egalitarian across the tech landscape.
“Cloud is the future, and it shouldn’t be exclusive,” said PacketFabric CEO Dave Ward. “That’s why we sought a way to democratize it. Now with PacketFabric’s flat rate pricing, companies from emerging businesses to large enterprises can have affordable access to the cloud.”
According to Gartner, “cost optimization will be crucial to drive cloud adoption, and by 2024, all legacy applications will be migrated to public cloud infrastructure.”
“They say you can’t have it good, fast and cheap, but now you can have all three with PacketFabric’s flat rate, cloud connectivity pricing,” continued Ward. “We’ve been disrupting the market since we launched PacketFabric’s Network-as-a-Service (NaaS) platform in 2017, and we continue to lead the way forward.”
PacketFabric’s NaaS orchestrates and guarantees connectivity between collocation facilities, clouds, and offers private network interconnection across the globe. The NaaS platform is private, secure, reliable and scalable, plus it’s fully redundant. PacketFabric is a women-founded technology start-up, launched by industry veterans Jezzibell Gilmore, PacketFabric’s Chief Commercial Officer, and Anna Claiborne, Senior Vice President of Product and Engineering for PacketFabric.
Ward, a prolific technologist, expands on PacketFabric’s strategy in his recent blog post , “Democratizing Access to the Cloud, Disrupting the Business of Getting to the Cloud.”
About PacketFabric
PacketFabric redefines how the enterprise moves data by automating network connectivity services. Leveraging an entirely automated SDN-based network architecture and the latest in optical and packet switching technology, PacketFabric enables dynamic, real-time connectivity services between more than hundreds of premier colocation facilities across many global markets. The PacketFabric Network-as-a-Service (NaaS) platform delivers simple, cost-effective, and scalable network deployment via its advanced Application Program Interface (API) and web portal. PacketFabric was named one of the “10 Hottest Networking Startups in 2020” by CRN and a 2020 “Cool Vendor in Enhanced Internet Services and Cloud Connectivity” by Gartner. PacketFabric investors include NantWorks and Digital Alpha Advisors. For more information, visit packetfabric.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005337/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom